Curetis AG today announced the start of an additional prospective, multicenter clinical trial of its marketed Unyvero P50 Pneumonia Application to demonstrate its clinical and health economic value.
Curetis AG today announced the start of an additional prospective, multicenter clinical trial of its marketed Unyvero P50 Pneumonia Application to demonstrate its clinical and health economic value.